Biofrontera AG

Biofrontera to Present at Cowen and Company's 37th Annual Healthcare Conference

Business news for the stock market

Leverkusen (pta025/28.02.2017/13:00) - Biofrontera AG (FSE: B8F), the specialist for the treatment of sun-induced skin cancer, today announced that the Company is scheduled to present at Cowen and Company's 37th Annual Healthcare Conference, being held on March 6-8, 2017 in Boston, MA. Dr. Hermann Lübbert, the Company's Chief Executive Officer, is scheduled to present on Wednesday, March 8, 2017 at 11:20am ET, and will provide an overview of the Company and its business strategy.

Enquiries, please contact: Biofrontera AG
Thomas Schaffer, Chief Financial Officer
[phone]
[e-mail]

IR Germany: Brainwell Asset Solutions
Jürgen Benker
[phone]

IR UK: Seton Services
Toni Vallen
[phone]

IR and PR US: The Ruth Group
IR: Lee Roth / Tram Bui
[phone] / 7035
PR: Kirsten Thomas
[phone]

About Biofrontera
Biofrontera AG (FSE: B8F, ISIN DE0006046113) is a biopharmaceutical company specializing in the development, sale and distribution of drugs, medical devices and medical cosmetics for the care and treatment of skin diseases. Biofrontera's lead product is Ameluz®, a prescription drug which was initially approved and marketed in Europe and is now also approved in the U.S. in combination with its medical lamp BF-RhodoLED® for photodynamic therapy (PDT) treatment (light therapy) of mild and moderate actinic keratosis, a precursor to squamous cell carcinoma. Since January 2017 Ameluz® is also approved in the EU for the treatment of superficial and nodular basal cell carcinomas. Biofrontera is the first German pharmaceutical start-up company to obtain centralized EU and now U.S. approval for a medical device/drug it has developed itself.

For more information, visit http://www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.

(end)

emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor & public relations
phone: [phone]
e-mail: [e-mail]
website: www.biofrontera.com

ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate

[ source: http://www.pressetext.com/news/20170228025 ]